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Research Article
Impact of EGFR Genetic Variants on Glioma Risk
and Patient Outcome
Bruno Marques Costa1,2, Marta Viana-Pereira1,2, Ricardo Fernandes1,2, Sandra Costa1,2, Paulo Linhares3,
Rui Vaz3, Celine Pinheiro1,2, Jorge Lima4, Paula Soares4,5, Ana Silva6, Fernando Pardal6,
Julia Amorim7, Rui Nabic¸o7, Rui Almeida8, Carlos Alegria8, Manuel Melo Pires9, Celia Pinheiro10,
Ernesto Carvalho10, Pedro Oliveira11, Jose M. Lopes4,5, and Rui M. Reis1,2,12
Abstract
Background: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is
frequently implicated in human tumors. Three EGFR polymorphisms have been described as having a
transcriptional regulatory function: two single-nucleotide polymorphisms in the essential promoter region,
216G/T and191C/A, and a polymorphic (CA)n microsatellite sequence in intron 1. We aimed to elucidate
the roles of these EGFR polymorphisms in glioma susceptibility and prognosis.
Methods: We conducted a case–control study with 196 patients with glioma and 168 cancer-free controls.
Unconditional multivariate logistic regression models were used to calculate ORs and 95% confidence
intervals. A Cox regression model was used to evaluate associations with patient survival. False-positive
report probabilities were also assessed.
Results:None of the EGFR 216G/T variants was significantly associated with glioma risk. The 191C/A
genotype was associated with higher risk for glioma when the (CA)n alleles were classified as short for16 or
17 repeats. Independently of the (CA)n repeat cutoff point used, shorter (CA)n repeat variants were
significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma. In
all testedmodels with different (CA)n cutoff points, only191C/A genotype was consistently associated with
improved survival of patients with glioblastoma.
Conclusions:Ourfindings implicateEGFR191C/Aand the (CA)n repeat polymorphisms as risk factors for
gliomas, and suggest 191C/A as a prognostic marker in glioblastoma.
Impact: Our data support a role of these EGFR polymorphisms in determining glioma susceptibility, with
potential relevance for molecularly based stratification of patients with glioblastoma for individualized
therapies. Cancer Epidemiol Biomarkers Prev; 20(12); 2610–7. 2011 AACR.
Introduction
Glioma is a broad category of tumors divided into
histologic subgroups based on the type of glial cell of
origin or morphologic similarities between tumor and
normal glial cells: astrocytomas (astrocytic lineage), oli-
godendrogliomas (oligodendroglial lineage), and oligoas-
trocytomas (mixed lineage) are the major subtypes,
whereas ependymomas (ependymal lineage) are less
common (1, 2). They are themost commonprimary central
nervous system tumors and account for approximately
80% of those that are malignant (2), for which efficient
therapies are not available (3–5). Despite recent advances
in the field of neuro-oncology, the prognosis of patients
with glioma remains very poor (6); in particular, patients
with glioblastoma, the most common and aggressive
(WHO grade IV) form of glioma, present median survival
time ranging from 12 to 15 months and the majority die
within 2 years (5). Their etiology remains largely
unknown: so far, only exposure to high-dose therapeutic
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radiation has been firmly established as a risk factor, but
otherplausible causes includegenetic syndromes, familial
aggregation, and genetic polymorphisms (7, 8). Equally
mysterious are truly clinically relevant prognostic fac-
tors for patients with glioma; patient age and clinical
performance status are clearly associated with patient
outcome, but recent evidences suggest that molecular
traits of tumor may also be important determinants of
prognosis (9–11).
The epidermal growth factor receptor (EGFR) pathway
plays prominent roles in regulating cell growth, apopto-
sis, and differentiation, a process that is tightly regulated
in normal epithelial cells (12). Deregulation of this path-
way can occur, for example, via somatic EGFRmutations
(e.g.,EGFRvIII), gene amplifications, and ligand-indepen-
dent constitutive stimulation signaling loops, and has
been implicated in several human tumors, including gli-
omas (13). Aberrant EGFR signalingmay ultimately affect
major hallmarks of cancer including tumor growth, inva-
sion, malignancy, and prognosis (13–16). In addition to
these somatic molecular alterations, germ line polymor-
phic variants in the EGF/EGFR pathway have also been
implicated in tumor risk, therapy response, and patient
outcome (17–20). We have previously shown that a func-
tional EGF polymorphism (EGF þ61) is associated with
glioma risk (19), which adds to the growing hypothesis
that polymorphisms in the EGFR pathway may be rele-
vant in the context of glioma.
Two single-nucleotide polymorphisms (SNP) were
recently found in the essential promoter regionof theEGFR
gene (216G/T and 191C/A), and the T variant in the
216 SNP was shown to increase the promoter activity in
anSp1-dependentmanner, resulting inhighergeneexpres-
sionboth in vitroand in vivo (21).A studybyCarpentier and
colleagues (22) implicated the216Tvariant as a risk factor
for glioblastoma. Likewise, a highly polymorphic micro-
satellite sequence (CA)n repeat was identified in the first
intron of EGFR (23). It has been proposed that transcrip-
tional activity of EGFR declines with increasing number of
(CA)n repeats, suggesting that this polymorphism may
play a role in cancer susceptibility (24).
In the context of thewidely acknowledged role of EGFR
signaling in gliomas and the functional relevance of par-
ticular EGFR polymorphisms, we investigated the rele-
vance of EGFR 216G/T, 191C/A, and (CA)n repeat
polymorphisms in glioma susceptibility andpatient prog-
nosis. To do so, we conducted a population-based case–
control study of 196 patients with glioma and 168 cancer-
free controls from Portugal.
Materials and Methods
Study population
We studied a total of 196 patients with glioma
recruited from Hospital S. Marcos, Braga, Hospital
S. Jo~ao, and Hospital S. Antonio. Tumors were classified
by experienced neuropathologists according to WHO
standards (1). The control group is composed of 168
cancer-free individuals randomly selected from blood
donors’ bank. All patients and controls were from
Northwest Portugal and of Caucasian ethnicity. Table
1 summarizes the clinicopathologic features of patients
and controls. This study was conducted in accordance
with institutional ethical committees. Blood samples
were obtained following informed signed consent. All
the samples enrolled were unlinked and unidentified
from their donors.
Genotyping
Genomic DNA frompatients with gliomawas obtained
from blood (n¼ 70) or formalin-fixed, paraffin-embedded
tumor samples (n ¼ 126) as previously reported (19).
EGFR 216G/T and 191C/A genotyping was carried
out by PCR amplification of the promoter region from
nucleotides 352 to 155 (Fw primer: 50-CTCCTCC-
TCCTCTGCTCCTC-30; Rv primer: 50-GGGGCTAGC-
TCGGGACTC-30), followed by RFLPwith BseRI and SacII
respectively, as previously described (21). To evaluate
Table 1. Clinicopathologic features of gliomas and controls
Groups (WHO grade) Number of cases Age, y (mean  SD) Male/female ratio
Controls 168 44.2  15.6 1.43
Gliomas (II–IV) 196 52.0  14.1 1.23
Astrocytoma (II-IV) 136 54.3  13.5 1.19
Diffuse astrocytoma (II) 15 40.1  13.5 0.36
Anaplastic astrocytoma (III) 5 37.4  11.6 All males
Glioblastoma (IV) 113 56.8  12.1 1.31
Gliosarcoma (IV) 3 59.7  5.69 0.50
Oligodendroglioma (II–III) 58 47.0  14.3 1.32
Oligodendroglioma (II) 30 42.2  16.1 1.31
Anaplastic oligodendroglioma (III) 28 52.0  10.0 1.33
Oligoastrocytoma 2 42.0  8.49 1.00
Anaplastic oligoastrocytoma (III) 2 42.0  8.49 1.00
EGFR/EGF Polymorphisms and Glioma
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EGFR (CA)n repeats in intron 1, a 5-carboxyfluorescein (5-
FAM)-labeledPCRreactionwas carriedout (Fwprimer: 5-
FAM–labeled 50-GGCTCACAGCAAACTTCTCC-30; Rv
primer: 50-AAGCCAGACTCGCTCATGTT-30) and the
products subsequently analyzedby single capillary genet-
ic analysis, as previously described (25). Briefly, PCR
cycles were 95C for 7 minutes; followed by 35 cycles of
95C for 45 seconds, 60C for 30 seconds, and 72C for 30
seconds; and a final step at 72C for 7 minutes. PCR
fragments ranging from 194 to 212 bp containing the
polymorphic region were obtained. One microliter of
PCR product and 0.6 mL of GeneScan 500 TAMRA size
standard (Applied Biosystems) were mixed with 14.4 mL
of formamide. PCR products were then separated using
an ABI Prism 310 (Applied Biosystems), and the frag-
ment lengths were determined with GeneScan Analysis
software version 3.7 (Applied Biosystems).
Data analyses and statistical methods
EGFR 216G/T and 191C/A groups were catego-
rized as previously described (21). Because EGFR
(CA)n repeats vary between n ¼ 14 and n ¼ 23 and
considering different approaches used in other studies
(26–30), we evaluated EGFR (CA)n repeat length on the
basis of 2 different methods. First, by the genotype-
based method (26, 30), the genotypes of EGFR (CA)n
repeat were categorized into 3 groups considering a
cutoff point of 17 (CA) repeats: homozygous short (SS)
contained 2 short alleles (both alleles 17 CA repeats),
homozygous long (LL) contained 2 long alleles (both
alleles >17 CA repeats), and heterozygous short/long
(SL) contained one short (17) and one long (>17)
allele. Because the cutoff value to consider short and
long alleles has been somewhat controversial in the
literature (30–33), we also tested 2 additional cutoff
values to define short alleles with 16 and 18 CA
repeats, and long alleles with >16 and >18 CA repeats,
respectively (33). Second, we investigated the EGFR
(CA)n repeat polymorphism by the summed allele
lengths method (28), where individuals were catego-
rized into short (sum of alleles length <36) or long (sum
of alleles length  36).
The x2 test was used to assess whether the observed
allele distributions of all polymorphisms were in Hardy–
Weinberg equilibrium in the control group. ORs and 95%
confidence intervals (95% CI) for the effect of EGFR
variants on the risk for each glioma type were estimated
by multivariate logistic regression analyses, adjusted for
EGF þ61A/G genotype, which was previously reported
to affect glioma susceptibility (19), and patient age (as a
continuous variable) and sex. The false-positive report
probability (FPRP) was calculated for significant associa-
tions observed inmultivariate tests according to the study
of Wacholder and colleagues (34). Associations between
EGFR variants [216G/T, 191C/A, and (CA)n repeat]
and patient survival were assessed using a multivariate
Cox regression model adjusted for EGF þ61A/G, patient
age, and sex (35).
Results
EGFR 216G/T, 191C/A, and (CA)n repeat
polymorphisms and risk of glioma
We studied a total of 196 patients with glioma and 168
cancer-free control individuals. Successful determination
of EGFR genotypes was achieved for all samples. The
distributions ofEGFþ61A/G,EGFR216G/T, and (CA)n
allele frequencies in the control group were in Hardy–
Weinberg equilibrium (P¼ 0.121,P¼ 0.899, andP¼ 0.150,
respectively); however,EGFR191C/Aalleles in controls
were not in equilibrium (P ¼ 0.034). A summary of
clinicopathologic features of the controls and cases is
presented in Table 1.
The frequencies of each EGFR genotype in controls and
cases arepresented inTable 2. TheEGFR allele frequencies
in our cancer-free control population are similar to those
found in other control populations (21, 31, 33). The most
frequent genotypes for each polymorphism in the control
group (homozygous 216G/G, homozygous 191C/C,
and heterozygous (CA)n repeat SL) were considered as
references. To assess associations between each variant of
the studied EGFR polymorphisms and risk for glioma, we
used an unconditional multivariate logistic regression
analysis adjusted for potential confounding variables
(EGFþ61A/Ggenotype, patient age, and sex). The control
group was compared with all glioma cases (WHO grades
II–IV) and also with glioblastoma (WHO grade IV) and
oligodendroglioma (WHO grades II and III; Table 2), as
thesewere themost frequent subtypes in our series (Table
1).
No statistically significant associations were found
between EGFR 216G/T genotype variants and risk for
glioma, glioblastoma, or oligodendroglioma (Table 2; all
values of P > 0.05). In contrast, when compared with the
191C/C reference genotype, the heterozygous 191C/
A genotype was significantly associated with increased
risk for glioma (OR¼ 1.81; 95% CI, 1.01–3.24; Table 2). No
significant associations between the 191A/A genotype
and risk for glioma, glioblastoma, or oligodendroglioma
were found (Table 2; all values ofP > 0.05). In addition, the
SS genotype of (CA)n repeat (considering short alleles17
CA repeats) was significantly associated with increased
risk for glioma (OR ¼ 2.38; 95% CI, 1.42–3.98), glioblas-
toma (OR ¼ 2.25; 95% CI, 1.20–4.25), and oligodendro-
glioma (OR ¼ 2.45; 95% CI, 1.17–5.12), as well as the LL
genotype was significantly associated with increased risk
for glioma (OR ¼ 1.95; 95% CI, 1.02–3.73). As expected
(19), EGFþ61A/G andG/G genotypes were significantly
associated with increased risk for glioma (OR¼ 1.75; 95%
CI, 1.03–2.96 and OR ¼ 1.90; 95% CI, 1.03–3.52,
respectively; Table 2), particularly oligodendroglioma
(OR ¼ 2.80; 95% CI, 1.18–6.67 and OR ¼ 2.75; 95% CI
1.06–7.09, respectively; Table 2) and nearly statistically
significant for glioblastoma (OR ¼ 1.72; 95% CI, 0.91–3.26
and OR ¼ 1.92; 95% CI, 0.91–4.03, respectively; Table 2).
When other cutoff values were used to classify short
and long alleles for the (CA)n repeat polymorphism,
Costa et al.
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specificallyn¼ 16 orn¼ 18 (i.e., S 16 andL> 16, or S 18
and L > 18, respectively), similar results were obtained;
particularly, the (CA) repeat homozygous SS genotype
was again significantly associatedwith increased risks for
glioma, glioblastoma, and oligodendroglioma both for a
cutoff value of S  16 repeats (Supplementary Table S1)
and S  18 repeats (Supplementary Table S2). The LL
genotype was also associated with increased risk for
glioma and glioblastoma for the cutoff value of S  16
(Supplementary Table S1) and for glioblastoma only for
the cutoff value of S  18 (Supplementary Table S2). Of
note, the heterozygous 191C/A genotype was also
associated with increased risk for glioma when the
cutoff value for (CA)n short and long repeats was 16
(Supplementary Table S1) but not in the case of a cutoff
value of 18 repeats (Supplementary Table S2). We also
analyzed the associations between EGFR variants and
risk considering the sum of alleles for the (CA)n repeat
polymorphism (28), which in our series varied from 29
to 41 repeats. Because the median value for the sum of
alleles in the control group was 36, we categorized the
sum of alleles as short <36 and long  36 but none of the
EGFR variants were significantly associated with risk in
this analysis (Supplementary Table S3).
The calculation of FPRP showed that all of the above-
mentioned EGFR associations with risk remained note-
worthy (FPRP  0.5) when a prior probability of associ-
ation of 10% or greater was considered (Table 3). This was
also the case for EGF þ61A/G associations, except in the
case of the G/G genotype in oligodendroglioma risk
(FPRP ¼ 0.562; Table 3). For a prior probability of 5% or
more, only the associations between (CA)n SS genotype
and risk for glioma and glioblastoma remained notewor-
thy, which remained significant even for a prior proba-
bility of 1% in the case of glioma risk (Table 3).
Taken together, these data strongly suggest that shorter
variants of the EGFR intron 1 (CA)n repeat polymorphism
increase the risk for gliomas, particularly glioblastoma
and oligodendroglioma.
EGFR 216G/T, 191C/A, and (CA)n repeat
polymorphisms and survival of patients with
glioblastoma
In a subset of patients with glioblastoma, we also had
available follow-up data (n ¼ 63). Thus, we investigated
the associations between each EGFR variant (216G/T,
191C/A, and (CA)n repeat) and overall survival by a
multivariate Cox proportional hazardmodel, adjusted for
EGF þ61A/G, patient age, and sex.
None of the EGFR 216G/T variants was associated
with survival of patients with glioblastoma (Table 4;
Supplementary Tables S4–S6 when the (CA)n repeat var-
iants were classified considering a cutoff value of S  17,
S  16, S  18, or sum of alleles < 36, respectively).
Table 2. Multivariate logistic regression analysis of associations between EGFR/EGF polymorphisms and
risk for glioma groups
Polymorphism Control Glioma
(grades
II–IV)
OR (95% CI) Glioblastoma
(grade IV)
OR (95% CI) Oligodendroglioma
(grades II–III)
OR (95% CI)
EGFR 216G/T
G/G 77 91 — 55 — 28 —
G/T 74 85 1.12 (0.68–1.84) 45 1.09 (0.58–2.03) 25 1.01 (0.49–2.07)
T/T 17 20 1.15 (0.52–2.59) 13 1.30 (0.50–3.40) 5 1.02 (0.31–3.40)
EGFR 191C/A
C/C 130 140 — 77 — 41 —
C/A 32 49 1.81 (1.01–3.24) 30 1.97 (0.96–4.03) 16 2.08 (0.93–4.63)
A/A 6 7 0.68 (0.19–2.45) 6 0.88 (0.21–3.70) 1 0.47 (0.05–4.84)
EGFR (CA)n repeat
a
SL 92 75 — 42 — 23 —
LL 28 40 1.95 (1.02–3.73) 25 2.14 (0.96–4.76) 10 1.83 (0.68–4.94)
SS 48 81 2.38 (1.42–3.98) 46 2.25 (1.20–4.25) 25 2.45 (1.17–5.12)
EGF þ61A/G
A/A 57 47 — 30 — 9 —
A/G 73 96 1.75 (1.03–2.96) 54 1.72 (0.91–3.26) 32 2.80 (1.18–6.67)
G/G 38 53 1.90 (1.03–3.51) 29 1.92 (0.91–4.03) 17 2.75 (1.06–7.09)
Age 1.04 (1.02–1.06) 1.07 (1.04–1.09) 1.02 (1.00-1.04)
Sex
Female 69 88 — 49 — 25 —
Male 99 108 0.95 (0.60–1.49) 64 1.02 (0.59–1.78) 33 0.98 (0.51–1.88)
NOTE: Bold-faced values indicate signiﬁcant difference at 5% level.
a(CA)n repeat considered short  17 and long > 17.
EGFR/EGF Polymorphisms and Glioma
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In contrast, the heterozygous 191C/A genotype was
significantly associatedwith improved overall survival of
patients with glioblastoma, as compared with homozy-
gous 191C/C, which was consistent across all analyses,
that is, when (CA)n alleles were classified as S 17 (OR¼
0.37; 95%CI, 0.16–0.88; Table 4), S 16 (OR¼ 0.35; 95%CI,
0.15–0.82; Supplementary Table S4), S  18 (OR ¼ 0.37;
95% CI, 0.16–0.82; Supplementary Table S5), or sum of
alleles < 36 (OR¼ 0.39; 95% CI, 0.17–0.86; Supplementary
Table S6).
The homozygous SS and LL (CA)n repeat genotypes
were also significantly associatedwith a longer survival of
patientswithglioblastomawhen the (CA)n repeat variants
were classified as S 17 (OR¼ 0.33; 95% CI, 0.11–0.95 for
LL genotype and OR ¼ 0.41; 95% CI, 0.18–0.93 for SS
genotype; Table 4). In the case of the SS genotype, this
association with longer survival was maintained when a
cutoff value of S 16 was considered (OR¼ 0.42; 95% CI,
0.18–0.95; Supplementary Table S4).
FPRP calculations showed that the association between
191C/A and (CA)n repeat SS genotypes and longer
survival of patientswith glioblastoma remained notewor-
thy for a prior probability of association of 10% or more
(FPRP < 0.5 for all associations),whichwas not the case for
LL genotypes (FPRP > 0.5, data not shown).
Taken together, these data strongly suggest that EGFR
191C/A and intron 1 (CA)n repeat polymorphisms are
prognostic markers in patients with glioblastoma, where-
as 216G/T variants do not seem to predict the outcome
of patients with glioblastoma.
Discussion
Gliomas are the most frequent and malignant primary
central nervous system tumors. These result inmore years
of life lost than do any other tumors (36) and are a
significant source of cancer-related death (37). It is gen-
erally assumed that genetic and environmental factors
contribute to gliomagenesis, but the etiology of gliomas
remains very poorly understood. Presently, one of the
several lines of brain tumor research focuses on the rel-
evance of germ linegenetic polymorphisms inglioma risk,
grade, prognosis, and response to specific therapies. We
have recently shown that an SNP in the EGF gene (which
encodes one of themainEGFR ligands),EGFþ61A/G, has
functional consequences and associated the G allele with
increased risk for glioma, particularly glioblastoma and
oligodendroglioma (19).
The EGFR pathway is commonly altered in gliomas.
Approximately 50% of glioblastomas show EGFR ampli-
fication and overexpression, 40% of which express the
mutant form EGFRvIII, resulting in constitutive activation
of the EGFR pathway (13, 38–40). Previously, Carpentier
and colleagues (22) showed an association between the
216T allele and increased risk for glioblastoma. We
attempted to replicate these findings, and examined, for
the first time, the implication of 216G/T and 191C/A
SNPs in other types of glioma. In opposition to the results
of thestudyofCarpentierandcolleagues,wehavenot seen
association betweenEGFR216T allele and increased risk
for glioblastomas or any other glioma subtype. This dis-
crepancy may be partially explained by distinct popula-
tion sampling and the fact that we conducted a logistic
regression adjusted for 2 other EGFR polymorphisms,
together with EGF þ61A/G, patient age, and sex. Impor-
tantly, the allele distribution of the 216G/T polymor-
phism in the control cancer-free population, we report
here (67.9% G, 32.1% T, n ¼ 168) is very similar to that
reportedbyother studies [68.3%G,31.7%T,n¼60 (ref. 21);
68.2% G, 31.8% T, n ¼ 22 (ref. 41)]. Inversely, the study of
Table 3. FPRP for signiﬁcant associations with risk
Polymorphism OR (95% CI) Powera Reported P Prior probability
0.1 0.05 0.01 0.001
Glioma risk
EGFR 191C/A (C/C ref.) 1.81 (1.01–3.24) 0.632 0.046 0.395 0.579 0.878 0.980
EGFR (CA)n LL (SL ref.) 1.95 (1.02–3.73) 0.530 0.044 0.425 0.609 0.890 0.988
EGFR (CA)n SS (SL ref.) 2.38 (1.42–3.98) 0.254 0.001 0.033 0.066 0.270 0.789
EGF þ61A/G (A/A ref.) 1.75 (1.03–2.96) 0.691 0.037 0.325 0.504 0.841 0.982
EGF þ61G/G (A/A ref.) 1.90 (1.03–3.51) 0.565 0.040 0.391 0.576 0.876 0.986
Glioblastoma risk
EGFR (CA)n SS (SL ref.) 2.25 (1.20–4.25) 0.358 0.012 0.238 0.398 0.775 0.972
Oligodendroglioma risk
EGFR (CA)n SS (SL ref.) 2.45 (1.17–5.12) 0.295 0.017 0.344 0.525 0.852 0.998
EGF þ61A/G (A/A ref.) 2.80 (1.18–6.67) 0.224 0.020 0.447 0.630 0.899 0.989
EGF þ61G/G (A/A ref.) 2.75 (1.06–7.09) 0.255 0.036 0.562 0.730 0.934 0.993
NOTE: Bold-faced values indicate the FPRP  0.5 for the most likely prior probability.
aEstimation of statistical power to detect an OR of 2.0 with an a level equal to the observed P value.
Costa et al.
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Carpentier and colleagues shows a significantly different
distributionof216G/Talleles in thecontrolgroup(53.2%
G, 46.8% T, n ¼ 176) when compared with our and others
data [x2 (3)¼19.4,P<0.001] (21, 41). Even though theallele
frequencies of this SNP vary greatly based on the ethnic
background (21), this feature cannot explain the observed
differences because all patients in our and others studies
(21, 22, 41) were Caucasians. Concerning the 191C/A
SNP, we observed that the heterozygous 191C/A
genotype was associated with increased risk for glioma.
A recent study by Schwartzbaum and colleagues (42)
identified 3 EGFR SNPs consistently associated with glio-
blastoma risk across 4 independent data sets. In
addition, these SNPs were highly correlated with 4 other
EGFRSNPspreviously foundtobesignificantlyassociated
with risk for glioma (43). Collectively, these and our data
seem to support EGFR SNPs as potential risk factors for
glioma.
Several studies suggest that EGFR expression is depen-
dent on the number of the intron 1 (CA)n repeats
(28, 30, 44, 45). In addition, this polymorphism has been
associatedwith risk of breast, lung, and colorectal cancers
(31–33) butwas never studied in gliomas. In this study,we
provide the first evidence on the relevance of the EGFR
(CA)n repeat length polymorphism in glioma risk and
patient survival. Because different criteria have been
published for the analysis of this polymorphism and no
consensual cutoff point exists to distinguish short and
long EGFR (CA)n repeat alleles (30–33), we used 3 differ-
ent cutoff points to covermost of the previously published
analysis (considering short alleles 16, 17, or 18 CA
repeats) and evaluated the (CA)n repeat by the genotype,
and the sum of the alleles length (considering the cutoff
point for the sum of alleles as the median value in our
control group). Our data show that the homozygous SS
genotype of the (CA)n repeat polymorphism was asso-
ciated with increased risk for glioma, glioblastoma, or
oligodendroglioma, regardless of the selected cutoff
point. The homozygous LL genotype was also found
to be associated with increased risk for glioma and
glioblastoma but only in some of the tested cutoff
values. Thus, caution must be taken in the interpretation
of the results and validation in an independent series is
required.
Investigating the prognostic value of these 3 EGFR
polymorphisms, we found a significant association
between the heterozygous 191C/A genotype and
improved survival of patients with glioblastoma, regard-
less of the criteria used for the cutoff value of the (CA)n
repeat genotypes in the multivariate Cox model (Table 4,
Supplementary Tables S4–S6). The SS and LL genotypes
for the (CA)n repeat polymorphism were also associated
with a better survival of patients with glioblastoma but
only for specific cutoff values (SSwhen S 17 or S 16; LL
when S 17); thus, the clinical relevance of this polymor-
phism warrants further confirmation.
In our study, the genotype assays of most patients
with glioma were carried out in tumor tissue, raising the
possibility that somatic alterations in the EGFR locus
(7p12) could lead to misgenotyping. However, we
believe that this is not the case because of the following
reasons: (i) the overall distribution of EGFR 216 and
191 and (CA)n repeat genotypes and alleles was not
statistically different for the group of patients whose
genotyping was done in DNA from blood or tumor
tissue (P ¼ 0.241 for EGFR 216; P ¼ 0.176 for EGFR
191; P ¼ 0.155 for (CA)n repeats; data not shown);
(ii) genotyping of all 3 polymorphisms was done with
100% concordance in 20 glioma cases from whom DNA
was available from both peripheral blood and tumor
tissue; (iii) we found no statistically significant associa-
tions between EGFR polymorphic variants and partic-
ular EGFR molecular alterations (EGFR amplification
and EGFRvIII mutation; Supplementary Table S7)
we had previously analyzed in a subset of tumors
(13). Accordingly, in lung cancer, it was previously
shown for the (CA)n repeats polymorphism that regard-
less the amplification status there was 100% concor-
dance in the genotyping of tumor and nontumor tissues
of 450 cases (15).
Table 4. Multivariate Cox proportional hazard
model analysis of associations between EGFR/
EGF polymorphisms and survival of patients
with glioblastoma (adjusted for patient age and
sex)
Polymorphism Glioblastoma
(grade IV)
OR (95% CI)
EGFR 216G/T
G/G 33 —
G/T 23 0.49 (0.23–1.01)
T/T 7 0.61 (0.21–1.73)
EGFR 191C/A
C/C 41 —
C/A 18 0.37 (0.16–0.88)
A/A 4 0.56 (0.12-2.69)
EGFR (CA)n repeat
a
SL 17 —
LL 17 0.33 (0.11–0.95)
SS 29 0.41 (0.18–0.93)
EGF þ61A/G
A/A 16 —
A/G 28 1.06 (0.47–2.38)
G/G 19 2.10 (0.89–4.99)
Age 1.00 (0.97–1.03)
Sex
Female 25 —
Male 38 1.02 (0.54–1.92)
NOTE: Bold-faced values indicate signiﬁcant difference at
5% level.
a(CA)n repeat considered short  17 and long > 17.
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In summary, our data consistently indicate that EGFR
intron 1 homozygous (CA)n repeat short genotypes confer
higher susceptibility to develop different histologic enti-
ties of glioma, and implicate the heterozygous 191C/A
genotype as a predictive marker of worse survival in
patients with glioblastoma. Because EGFR is one of the
most frequently alteredmolecules in high-grade glioma, it
is natural to think of it as an attractive therapeutic target.
Therefore, further studies are warranted to investigate
how these EGFR polymorphisms may affect response of
patients with glioma to EGFR-targeting therapies.
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